gcar1
Cell therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 6, 2023 (NCT06827886)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transmembrane glycoprotein NMBImmunity, passive
GPNMB immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07297667 | Phase 1 | Jan 31, 2026 | Canadian Cancer Trials Group, University of Calgary |
| NCT07104682 | Early Phase 1 (Phase 1) | Aug 8, 2025 | University of Calgary |
| NCT06789081 | Early Phase 1 (Phase 1) | Apr 30, 2025 | University of Calgary |
| NCT06813417 | Early Phase 1 (Phase 1) | Jan 30, 2025 | Alberta Precision Laboratories, University of Calgary |
| NCT06827886 | Early Phase 1 (Phase 1) | Sep 6, 2023 | University of Calgary |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Calgary | Academic/Hospital | 5 | 4 | 1 | 2023 |
| Alberta Precision Laboratories | For profit | 1 | 0 | 1 | 2025 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2026 |
3 organizations
Page 1 / 1